Prospective Study Into the Performance of the MicroPhage S. Aureus/MSSA/MRSA Test Direct From Blood Culture Positives

MicroPhage

Status: Completed

Conditions: Bacteremia

Treatments: Device: MicroPhage S. aureus/MSSA/MRSA Blood Culture Test

Study type: Observational

Funder types: Industry

Identifiers

NCT01184339

MP2009-B

Details and patient eligibility

About

Direct in-vitro identification of S. aureus, methicillin-sensitive S. aureus (MSSA), and methicillin-resistant S. aureus (MRSA) from positive blood cultures by MicroPhage's bacteriophage-based diagnostic platform, two gold-standard reference methods, and two predicate devices with similar indications for use.

Full description

This is a multi-center, FDA clinical study designed to investigate the safety and performance of the MicroPhage S. aureus/MSSA/MRSA test direct from blood culture positives. Informed consent is not anticipated, as this is a laboratory performance study with no patient intervention. The MicroPhage Test will be compared to site standards of care, market-available rapid tests, two predicate tests, and two disk diffusion tests for antimicrobial susceptibility. The study will last approximately 4-6 months (Bactec), dependent on the accrual rate of each institution.

This study is designed to support the following product indications for use:

The MicroPhage S. aureus/MSSA/MRSA Blood Culture Test is a qualitative in vitro diagnostic test for the rapid identification of Staphylococcus aureus and determination of methicillin susceptibility (MSSA) or methicillin resistance (MRSA) directly from positive blood cultures.

The test uses bacteriophage amplification to rapidly and phenotypically identify the presence of S. aureus and assess the response of the target organism to cefoxitin as an analog to methicillin.

This test is performed on positive blood cultures.

Subculturing of positive blood cultures is necessary for further susceptibility test determinations.

Results of the study analysis will be in the form of descriptive statistics (mean, median, standard deviation, frequencies) for all study variables. Associations among variables will be presented using correlation coefficients, as well as odds ratios and parameter estimates from multivariable regression (linear and logistic) where applicable.

Enrollment: 1,165 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Blood culture positive samples from subjects aged 18+, with any of the following bottle types:
• BD Bactec Standard Aerobic and Anaerobic,
• BD Bactec Plus Aerobic and Anaerobic,
• Completion of the MicroPhage test protocol on the sample.

Exclusion criteria

• Samples from subjects under 18 years of age,
• Samples from any other not included bottle types,
• Samples from blood culture positives over 24 hours from alarm,
• Samples deemed contaminated,
• Mislabeled / misidentified samples or data without documented corrections,
• Violations and/or deviations from the MicroPhage test protocol and/or other included test protocols under study.

Trial design

1,165 participants in 2 patient groups

Standard of Care

Description:

Current practice methods for the determination of bacteremia, specific to site practice.

Treatment:

Device: MicroPhage S. aureus/MSSA/MRSA Blood Culture Test

Gold Standard ID/AST

Description:

Identification of S. aureus: coagulase positive, catalase positive, Staphaurex positive, and PYR negative, if performed). Determination of MRSA:S. aureus gold standard and \</=11mm OXA DD or \</=21mm CFX DD. Determination of MSSA: S. aureus gold standard and \>/=13mm OXA DD or \>/=22mm CFX DD.

Treatment:

Device: MicroPhage S. aureus/MSSA/MRSA Blood Culture Test